北海康成-B(01228.HK)上半年期內經調整虧損大幅縮窄82.7%,與百洋醫藥進行戰略合作
格隆匯8月31日丨北海康成-B(01228.HK)公佈中期業績,2025年上半年,期內溢利增加約人民幣3.065億元,由截至2024年6月30日止六個月的虧損人民幣2.473億元扭虧爲盈至溢利人民幣5920萬元,主要歸因於其他收入及收益增加以及銷售及分銷開支、研發開支及行政開支減少,部分被收益減少所抵銷。
期內經調整虧損由截至2024年6月30日止六個月的人民幣2.162億元減少人民幣1.789億元或82.7%至截至2025年6月30日止六個月人民幣3740萬元。期內經調整虧損乃通過調整報告期間內國際財務報告準則溢利╱(虧損)人民幣5920萬元得出,不包括以股份爲基礎的付款開支、撇銷使用權資產及租賃終止的收益╱(虧損)的影響。
於2025年8月,公司開始與百洋醫藥進行戰略合作,據此,(i)公司委任百洋醫藥的若幹附屬公司爲公司的獨家合同銷售組織提供市場推廣服務,及倘百洋醫藥的有關附屬公司要求,同時作爲公司的獨家分銷商,於中國內地、香港及澳門推廣海芮思®、邁芮倍®及戈芮寧®,公司自其收取的戰略合作費爲人民幣50百萬元;及(ii)百洋醫藥的一家附屬公司認購74,971,468股公司股份,於公告日期佔公司經擴大已發行股份總數之14.99%,據此,公司收取總代價約爲1億港元。
儘管2025年上半年面臨挑戰,但於成功實施精簡產品線及提升資本效率的措施後,公司重新專注於公司的業務及營運,公司對2025年下半年持樂觀態度。此外,透過與百洋醫藥深化合作及百洋醫藥爲北海康成帶來的新資本,公司預期推動提高關鍵業務領域的執行力,爲公司未來增長加強運營基礎,並在2025年下半年取得更優異的業績。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.